<DOC>
	<DOCNO>NCT01346254</DOCNO>
	<brief_summary>Development New-Onset Diabetes Transplantation ( NODAT ) common serious complication kidney transplantation . Patients develop NODAT increase risk loss transplant organ disease cardiovascular system . It believe many patient development overt NODAT precede phase impair glucose tolerance call pre-diabetes . This study aim improve glucose metabolism patient kidney transplantation pre-diabetic metabolic state . Patients exhibit impaired glucose tolerance ( IGT ) kidney transplantation randomize either receive vildagliptin ( Galvus ) , pioglitazone ( Actos ) placebo three month . The investigator hypothesize treatment vildagliptin pioglitazone lead improved glycemic control compare placebo .</brief_summary>
	<brief_title>Glucose Control Pre-Diabetic Renal Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Time since renal transplantation &gt; 6 month Stable graft function Routine OGTT perform , prediabetes diagnose pathological OGTT ( 2h , 75 g glucose , glucose level 140 200 mg/dl ) Informed consent patient Patients type 1 type 2 diabetes Patients NODAT ( 2h glucose level OGTT &gt; 200 mg/dl ) allergy vildagliptin pioglitazone pregnancy GFR &lt; 15ml/min/1.73 need dialysis hepatic impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>81 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword />
</DOC>